APO Research
Talk to an analyst

APO RESEARCH · REPORT

Psychiatric API

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Psychiatric API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchPsychiatric API Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Psychiatric API Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Psychiatric API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Psychiatric API Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Psychiatric API Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Psychiatric API market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Psychiatric API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Psychiatric API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Psychiatric API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Psychiatric API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Psychiatric API include Yaopharma, Yangtze River Pharmaceutical, Sichuan Chuanda West China Pharmaceutical, Ren An Pharmaceutical, Eli Lilly, Kanghong Pharmaceutical, Pfizer, Huahai Pharmaceutical and Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Psychiatric API market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Psychiatric API and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Psychiatric API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Psychiatric API market size, projected growth trends, production technologies, key applications, and end-use industries.

Psychiatric API Segment by Company

Yaopharma

Yangtze River Pharmaceutical

Sichuan Chuanda West China Pharmaceutical

Ren An Pharmaceutical

Eli Lilly

Kanghong Pharmaceutical

Pfizer

Huahai Pharmaceutical

Hengrui Pharmaceuticals

Herui Pharmaceutical

Dongting Pharmaceutical

Brilliant Pharmaceutical

Salutas Pharma

Germany Pharmaceutical

Dr.Reddy's Laboratories

Bora Pharmaceutical

Psychiatric API Segment by Type

Venlafaxine

Paroxetine

Duloxetine

Olanzapine

Others

Psychiatric API Segment by Application

Generalized Anxiety Disorder

Schizophrenia

Fibromyalgia

Major Depressive Disorder

Others

Psychiatric API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psychiatric API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Psychiatric API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psychiatric API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Psychiatric API market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Psychiatric API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Psychiatric API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Psychiatric API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Psychiatric API Industry Trends Table 2. Psychiatric API Industry Drivers Table 3. Psychiatric API Industry Opportunities and Challenges Table 4. Psychiatric API Industry Restraints Table 5. Global Psychiatric API Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Psychiatric API Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Psychiatric API Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Psychiatric API Sales Market Share by Manufacturers Table 9. Global Psychiatric API Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Psychiatric API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Psychiatric API Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Psychiatric API Manufacturers, Product Type & Application Table 13. Global Psychiatric API Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Psychiatric API by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Venlafaxine Table 17. Major Manufacturers of Paroxetine Table 18. Major Manufacturers of Duloxetine Table 19. Major Manufacturers of Olanzapine Table 20. Major Manufacturers of Others Table 21. Global Psychiatric API Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Psychiatric API Sales by Type (2021-2026) & (k units) Table 23. Global Psychiatric API Sales by Type (2027-2032) & (k units) Table 24. Global Psychiatric API Sales Market Share by Type (2021-2026) Table 25. Global Psychiatric API Sales Market Share by Type (2027-2032) Table 26. Global Psychiatric API Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Psychiatric API Revenue by Type (2021-2026) & (k units) Table 28. Global Psychiatric API Revenue by Type (2027-2032) & (k units) Table 29. Global Psychiatric API Revenue Market Share by Type (2021-2026) Table 30. Global Psychiatric API Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Generalized Anxiety Disorder Table 32. Major Manufacturers of Schizophrenia Table 33. Major Manufacturers of Fibromyalgia Table 34. Major Manufacturers of Major Depressive Disorder Table 35. Major Manufacturers of Others Table 36. Global Psychiatric API Sales by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Psychiatric API Sales by Application (2021-2026) & (k units) Table 38. Global Psychiatric API Sales by Application (2027-2032) & (k units) Table 39. Global Psychiatric API Sales Market Share by Application (2021-2026) Table 40. Global Psychiatric API Sales Market Share by Application (2027-2032) Table 41. Global Psychiatric API Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 42. Global Psychiatric API Revenue by Application (2021-2026) & (k units) Table 43. Global Psychiatric API Revenue by Application (2027-2032) & (k units) Table 44. Global Psychiatric API Revenue Market Share by Application (2021-2026) Table 45. Global Psychiatric API Revenue Market Share by Application (2027-2032) Table 46. Global Psychiatric API Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Psychiatric API Sales by Region (2021-2026) & (k units) Table 48. Global Psychiatric API Sales Market Share by Region (2021-2026) Table 49. Global Psychiatric API Sales Forecasted by Region (2027-2032) & (k units) Table 50. Global Psychiatric API Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Psychiatric API Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. North America Psychiatric API Sales by Country (2021-2026) & (k units) Table 53. North America Psychiatric API Sales by Country (2027-2032) & (k units) Table 54. Europe Psychiatric API Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Europe Psychiatric API Sales by Country (2021-2026) & (k units) Table 56. Europe Psychiatric API Sales by Country (2027-2032) & (k units) Table 57. Asia Pacific Psychiatric API Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Asia Pacific Psychiatric API Sales by Country (2021-2026) & (k units) Table 59. Asia Pacific Psychiatric API Sales by Country (2027-2032) & (k units) Table 60. South America, Middle East and Africa Psychiatric API Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 61. South America, Middle East and Africa Psychiatric API Sales by Country (2021-2026) & (k units) Table 62. South America, Middle East and Africa Psychiatric API Sales by Country (2027-2032) & (k units) Table 63. Global Psychiatric API Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Psychiatric API Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Psychiatric API Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Psychiatric API Revenue Market Share by Region (2021-2026) Table 67. Global Psychiatric API Revenue Market Share by Region (2027-2032) Table 68. Yaopharma Company Information Table 69. Yaopharma Business Overview Table 70. Yaopharma Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Yaopharma Psychiatric API Product Portfolio Table 72. Yaopharma Recent Development Table 73. Yangtze River Pharmaceutical Company Information Table 74. Yangtze River Pharmaceutical Business Overview Table 75. Yangtze River Pharmaceutical Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Yangtze River Pharmaceutical Psychiatric API Product Portfolio Table 77. Yangtze River Pharmaceutical Recent Development Table 78. Sichuan Chuanda West China Pharmaceutical Company Information Table 79. Sichuan Chuanda West China Pharmaceutical Business Overview Table 80. Sichuan Chuanda West China Pharmaceutical Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Sichuan Chuanda West China Pharmaceutical Psychiatric API Product Portfolio Table 82. Sichuan Chuanda West China Pharmaceutical Recent Development Table 83. Ren An Pharmaceutical Company Information Table 84. Ren An Pharmaceutical Business Overview Table 85. Ren An Pharmaceutical Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Ren An Pharmaceutical Psychiatric API Product Portfolio Table 87. Ren An Pharmaceutical Recent Development Table 88. Eli Lilly Company Information Table 89. Eli Lilly Business Overview Table 90. Eli Lilly Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Eli Lilly Psychiatric API Product Portfolio Table 92. Eli Lilly Recent Development Table 93. Kanghong Pharmaceutical Company Information Table 94. Kanghong Pharmaceutical Business Overview Table 95. Kanghong Pharmaceutical Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Kanghong Pharmaceutical Psychiatric API Product Portfolio Table 97. Kanghong Pharmaceutical Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Pfizer Psychiatric API Product Portfolio Table 102. Pfizer Recent Development Table 103. Huahai Pharmaceutical Company Information Table 104. Huahai Pharmaceutical Business Overview Table 105. Huahai Pharmaceutical Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Huahai Pharmaceutical Psychiatric API Product Portfolio Table 107. Huahai Pharmaceutical Recent Development Table 108. Hengrui Pharmaceuticals Company Information Table 109. Hengrui Pharmaceuticals Business Overview Table 110. Hengrui Pharmaceuticals Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Hengrui Pharmaceuticals Psychiatric API Product Portfolio Table 112. Hengrui Pharmaceuticals Recent Development Table 113. Herui Pharmaceutical Company Information Table 114. Herui Pharmaceutical Business Overview Table 115. Herui Pharmaceutical Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Herui Pharmaceutical Psychiatric API Product Portfolio Table 117. Herui Pharmaceutical Recent Development Table 118. Dongting Pharmaceutical Company Information Table 119. Dongting Pharmaceutical Business Overview Table 120. Dongting Pharmaceutical Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Dongting Pharmaceutical Psychiatric API Product Portfolio Table 122. Dongting Pharmaceutical Recent Development Table 123. Brilliant Pharmaceutical Company Information Table 124. Brilliant Pharmaceutical Business Overview Table 125. Brilliant Pharmaceutical Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Brilliant Pharmaceutical Psychiatric API Product Portfolio Table 127. Brilliant Pharmaceutical Recent Development Table 128. Salutas Pharma Company Information Table 129. Salutas Pharma Business Overview Table 130. Salutas Pharma Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Salutas Pharma Psychiatric API Product Portfolio Table 132. Salutas Pharma Recent Development Table 133. Germany Pharmaceutical Company Information Table 134. Germany Pharmaceutical Business Overview Table 135. Germany Pharmaceutical Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Germany Pharmaceutical Psychiatric API Product Portfolio Table 137. Germany Pharmaceutical Recent Development Table 138. Dr.Reddy's Laboratories Company Information Table 139. Dr.Reddy's Laboratories Business Overview Table 140. Dr.Reddy's Laboratories Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Dr.Reddy's Laboratories Psychiatric API Product Portfolio Table 142. Dr.Reddy's Laboratories Recent Development Table 143. Bora Pharmaceutical Company Information Table 144. Bora Pharmaceutical Business Overview Table 145. Bora Pharmaceutical Psychiatric API Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Bora Pharmaceutical Psychiatric API Product Portfolio Table 147. Bora Pharmaceutical Recent Development Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Psychiatric API Distributors List Table 151. Psychiatric API Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Psychiatric API Product Image Figure 2. Global Psychiatric API Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Psychiatric API Market Size (2021-2032) & (US$ Million) Figure 4. Global Psychiatric API Sales (2021-2032) & (k units) Figure 5. Global Psychiatric API Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Psychiatric API Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Venlafaxine Image Figure 9. Paroxetine Image Figure 10. Duloxetine Image Figure 11. Olanzapine Image Figure 12. Others Image Figure 13. Global Psychiatric API Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Psychiatric API Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Psychiatric API Sales Market Share by Type (2021-2032) Figure 16. Global Psychiatric API Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Psychiatric API Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Psychiatric API Revenue Market Share by Type (2021-2032) Figure 19. Generalized Anxiety Disorder Image Figure 20. Schizophrenia Image Figure 21. Fibromyalgia Image Figure 22. Major Depressive Disorder Image Figure 23. Others Image Figure 24. Global Psychiatric API Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Psychiatric API Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Psychiatric API Sales Market Share by Application (2021-2032) Figure 27. Global Psychiatric API Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global Psychiatric API Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Psychiatric API Revenue Market Share by Application (2021-2032) Figure 30. North America Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 31. North America Psychiatric API Sales Market Share by Country (2021-2032) Figure 32. U.S. Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 33. Canada Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 34. Mexico Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Psychiatric API Sales Market Share by Country (2021-2032) Figure 37. Germany Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 38. France Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 39. U.K. Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 40. Italy Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 41. Netherlands Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Psychiatric API Sales Market Share by Country (2021-2032) Figure 44. China Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 45. Japan Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 46. South Korea Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 47. Southeast Asia Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 48. India Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 49. Australia Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Psychiatric API Sales Market Share by Country (2021-2032) Figure 52. Brazil Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 53. South Africa Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 54. Saudi Arabia Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 55. Turkey Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 56. Argentina Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 57. UAE Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 58. Egypt Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 59. Chile Psychiatric API Sales and Growth Rate (2021-2032) & (k units) Figure 60. Global Psychiatric API Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Psychiatric API Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Psychiatric API Revenue (2021-2032) & (US$ Million) Figure 63. North America Psychiatric API Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Psychiatric API Revenue (2021-2032) & (US$ Million) Figure 65. Europe Psychiatric API Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Psychiatric API Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Psychiatric API Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Psychiatric API Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Psychiatric API Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Psychiatric API Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Psychiatric API Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Venlafaxine
  • Paroxetine
  • Duloxetine
  • Olanzapine
  • Others
Applications
  • Generalized Anxiety Disorder
  • Schizophrenia
  • Fibromyalgia
  • Major Depressive Disorder
  • Others
Companies covered
  • Yaopharma
  • Yangtze River Pharmaceutical
  • Sichuan Chuanda West China Pharmaceutical
  • Ren An Pharmaceutical
  • Eli Lilly
  • Kanghong Pharmaceutical
  • Pfizer
  • Huahai Pharmaceutical
  • Hengrui Pharmaceuticals
  • Herui Pharmaceutical
  • Dongting Pharmaceutical
  • Brilliant Pharmaceutical
  • Salutas Pharma
  • Germany Pharmaceutical
  • Dr.Reddy's Laboratories
  • Bora Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Psychiatric API Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Psychiatric API Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Psychiatric API Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Psychiatric API Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Psychiatric API Market Dynamics
  1. 2.1 Psychiatric API Industry Trends
  2. 2.2 Psychiatric API Industry Drivers
  3. 2.3 Psychiatric API Industry Opportunities and Challenges
  4. 2.4 Psychiatric API Industry Restraints
3 Psychiatric API Market by Manufacturers
  1. 3.1 Global Psychiatric API Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Psychiatric API Sales by Manufacturers (2021-2026)
  3. 3.3 Global Psychiatric API Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Psychiatric API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Psychiatric API Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Psychiatric API Manufacturers, Product Type & Application
  7. 3.7 Global Psychiatric API Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Psychiatric API Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Psychiatric API Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Psychiatric API Tier 1, Tier 2, and Tier 3
4 Psychiatric API Market by Type
  1. 4.1 Psychiatric API Type Introduction
  2. 4.1.1 Venlafaxine
  3. 4.1.2 Paroxetine
  4. 4.1.3 Duloxetine
  5. 4.1.4 Olanzapine
  6. 4.1.5 Others
  7. 4.2 Global Psychiatric API Sales by Type
  8. 4.2.1 Global Psychiatric API Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Psychiatric API Sales by Type (2021-2032)
  10. 4.2.3 Global Psychiatric API Sales Market Share by Type (2021-2032)
  11. 4.3 Global Psychiatric API Revenue by Type
  12. 4.3.1 Global Psychiatric API Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Psychiatric API Revenue by Type (2021-2032)
  14. 4.3.3 Global Psychiatric API Revenue Market Share by Type (2021-2032)
5 Psychiatric API Market by Application
  1. 5.1 Psychiatric API Application Introduction
  2. 5.1.1 Generalized Anxiety Disorder
  3. 5.1.2 Schizophrenia
  4. 5.1.3 Fibromyalgia
  5. 5.1.4 Major Depressive Disorder
  6. 5.1.5 Others
  7. 5.2 Global Psychiatric API Sales by Application
  8. 5.2.1 Global Psychiatric API Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Psychiatric API Sales by Application (2021-2032)
  10. 5.2.3 Global Psychiatric API Sales Market Share by Application (2021-2032)
  11. 5.3 Global Psychiatric API Revenue by Application
  12. 5.3.1 Global Psychiatric API Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Psychiatric API Revenue by Application (2021-2032)
  14. 5.3.3 Global Psychiatric API Revenue Market Share by Application (2021-2032)
6 Global Psychiatric API Sales by Region
  1. 6.1 Global Psychiatric API Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Psychiatric API Sales by Region (2021-2032)
  3. 6.2.1 Global Psychiatric API Sales by Region (2021-2026)
  4. 6.2.2 Global Psychiatric API Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Psychiatric API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Psychiatric API Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Psychiatric API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Psychiatric API Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Psychiatric API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Psychiatric API Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Psychiatric API Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Psychiatric API Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Psychiatric API Revenue by Region
  1. 7.1 Global Psychiatric API Revenue by Region
  2. 7.1.1 Global Psychiatric API Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Psychiatric API Revenue by Region (2021-2026)
  4. 7.1.3 Global Psychiatric API Revenue by Region (2027-2032)
  5. 7.1.4 Global Psychiatric API Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Psychiatric API Revenue (2021-2032)
  8. 7.2.2 North America Psychiatric API Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Psychiatric API Revenue (2021-2032)
  11. 7.3.2 Europe Psychiatric API Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Psychiatric API Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Psychiatric API Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Psychiatric API Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Psychiatric API Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Yaopharma
  2. 8.1.1 Yaopharma Company Information
  3. 8.1.2 Yaopharma Business Overview
  4. 8.1.3 Yaopharma Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yaopharma Psychiatric API Product Portfolio
  6. 8.1.5 Yaopharma Recent Developments
  7. 8.2 Yangtze River Pharmaceutical
  8. 8.2.1 Yangtze River Pharmaceutical Company Information
  9. 8.2.2 Yangtze River Pharmaceutical Business Overview
  10. 8.2.3 Yangtze River Pharmaceutical Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Yangtze River Pharmaceutical Psychiatric API Product Portfolio
  12. 8.2.5 Yangtze River Pharmaceutical Recent Developments
  13. 8.3 Sichuan Chuanda West China Pharmaceutical
  14. 8.3.1 Sichuan Chuanda West China Pharmaceutical Company Information
  15. 8.3.2 Sichuan Chuanda West China Pharmaceutical Business Overview
  16. 8.3.3 Sichuan Chuanda West China Pharmaceutical Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sichuan Chuanda West China Pharmaceutical Psychiatric API Product Portfolio
  18. 8.3.5 Sichuan Chuanda West China Pharmaceutical Recent Developments
  19. 8.4 Ren An Pharmaceutical
  20. 8.4.1 Ren An Pharmaceutical Company Information
  21. 8.4.2 Ren An Pharmaceutical Business Overview
  22. 8.4.3 Ren An Pharmaceutical Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Ren An Pharmaceutical Psychiatric API Product Portfolio
  24. 8.4.5 Ren An Pharmaceutical Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Psychiatric API Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Kanghong Pharmaceutical
  32. 8.6.1 Kanghong Pharmaceutical Company Information
  33. 8.6.2 Kanghong Pharmaceutical Business Overview
  34. 8.6.3 Kanghong Pharmaceutical Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kanghong Pharmaceutical Psychiatric API Product Portfolio
  36. 8.6.5 Kanghong Pharmaceutical Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Psychiatric API Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Huahai Pharmaceutical
  44. 8.8.1 Huahai Pharmaceutical Company Information
  45. 8.8.2 Huahai Pharmaceutical Business Overview
  46. 8.8.3 Huahai Pharmaceutical Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Huahai Pharmaceutical Psychiatric API Product Portfolio
  48. 8.8.5 Huahai Pharmaceutical Recent Developments
  49. 8.9 Hengrui Pharmaceuticals
  50. 8.9.1 Hengrui Pharmaceuticals Company Information
  51. 8.9.2 Hengrui Pharmaceuticals Business Overview
  52. 8.9.3 Hengrui Pharmaceuticals Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hengrui Pharmaceuticals Psychiatric API Product Portfolio
  54. 8.9.5 Hengrui Pharmaceuticals Recent Developments
  55. 8.10 Herui Pharmaceutical
  56. 8.10.1 Herui Pharmaceutical Company Information
  57. 8.10.2 Herui Pharmaceutical Business Overview
  58. 8.10.3 Herui Pharmaceutical Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Herui Pharmaceutical Psychiatric API Product Portfolio
  60. 8.10.5 Herui Pharmaceutical Recent Developments
  61. 8.11 Dongting Pharmaceutical
  62. 8.11.1 Dongting Pharmaceutical Company Information
  63. 8.11.2 Dongting Pharmaceutical Business Overview
  64. 8.11.3 Dongting Pharmaceutical Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Dongting Pharmaceutical Psychiatric API Product Portfolio
  66. 8.11.5 Dongting Pharmaceutical Recent Developments
  67. 8.12 Brilliant Pharmaceutical
  68. 8.12.1 Brilliant Pharmaceutical Company Information
  69. 8.12.2 Brilliant Pharmaceutical Business Overview
  70. 8.12.3 Brilliant Pharmaceutical Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Brilliant Pharmaceutical Psychiatric API Product Portfolio
  72. 8.12.5 Brilliant Pharmaceutical Recent Developments
  73. 8.13 Salutas Pharma
  74. 8.13.1 Salutas Pharma Company Information
  75. 8.13.2 Salutas Pharma Business Overview
  76. 8.13.3 Salutas Pharma Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Salutas Pharma Psychiatric API Product Portfolio
  78. 8.13.5 Salutas Pharma Recent Developments
  79. 8.14 Germany Pharmaceutical
  80. 8.14.1 Germany Pharmaceutical Company Information
  81. 8.14.2 Germany Pharmaceutical Business Overview
  82. 8.14.3 Germany Pharmaceutical Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Germany Pharmaceutical Psychiatric API Product Portfolio
  84. 8.14.5 Germany Pharmaceutical Recent Developments
  85. 8.15 Dr.Reddy's Laboratories
  86. 8.15.1 Dr.Reddy's Laboratories Company Information
  87. 8.15.2 Dr.Reddy's Laboratories Business Overview
  88. 8.15.3 Dr.Reddy's Laboratories Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Dr.Reddy's Laboratories Psychiatric API Product Portfolio
  90. 8.15.5 Dr.Reddy's Laboratories Recent Developments
  91. 8.16 Bora Pharmaceutical
  92. 8.16.1 Bora Pharmaceutical Company Information
  93. 8.16.2 Bora Pharmaceutical Business Overview
  94. 8.16.3 Bora Pharmaceutical Psychiatric API Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bora Pharmaceutical Psychiatric API Product Portfolio
  96. 8.16.5 Bora Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Psychiatric API Value Chain Analysis
  2. 9.1.1 Psychiatric API Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Psychiatric API Production Mode & Process
  6. 9.2 Psychiatric API Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Psychiatric API Distributors
  9. 9.2.3 Psychiatric API Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst